RESUMEN
Rectal squamous cell carcinoma (SCC) is a rare tumor with unresolved etiology. Human immunodeficiency virus-infected individuals and solid organ transplant recipients experience >30-fold and approximately 3-fold elevated rates of rectal SCC, respectively, suggesting immunosuppression plays a role.1 Human immunodeficiency virus-infected homosexual men have >60-fold higher rates of rectal SCC, similar to anal SCC. These patterns, which differ from the more common rectal adenocarcinoma (AdCA), raise the possibility of shared etiology between rectal and anal SCC, with human papillomavirus type 16 (HPV16) being a likely candidate.2.
Asunto(s)
Carcinoma de Células Escamosas/patología , Papillomavirus Humano 16/genética , Infecciones por Papillomavirus/epidemiología , Neoplasias del Recto/patología , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Adenocarcinoma/virología , Neoplasias del Ano/metabolismo , Neoplasias del Ano/patología , Neoplasias del Ano/virología , Biomarcadores/metabolismo , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/virología , Estudios de Casos y Controles , ADN Viral/análisis , Proteínas de Unión al ADN/genética , Humanos , Hibridación in Situ , Queratinas/metabolismo , Proteínas Oncogénicas Virales/genética , Infecciones por Papillomavirus/virología , Neoplasias del Recto/metabolismo , Neoplasias del Recto/virología , Proteínas Represoras/genética , Factores de Transcripción/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Proteínas del Envoltorio Viral/genéticaRESUMEN
CONTEXT.: The Surveillance, Epidemiology, and End Results (SEER) cancer registry program is currently evaluating the use of archival, diagnostic, formalin-fixed, paraffin-embedded (FFPE) tissue obtained through SEER cancer registries, functioning as honest brokers for deidentified tissue and associated data. To determine the feasibility of this potential program, laboratory policies for sharing tissue for research needed to be assessed. OBJECTIVE.: To understand the willingness of pathology laboratories to share archival diagnostic tissue for cancer research and related policies. DESIGN.: Seven SEER registries administered a 27-item questionnaire to pathology laboratories within their respective registry catchment areas. Only laboratories that processed diagnostic FFPE specimens and completed the questionnaire were included in the analysis. RESULTS.: Of the 153 responding laboratories, 127 (83%) responded that they process FFPE specimens. Most (n = 88; 69%) were willing to share tissue specimens for research, which was not associated with the number of blocks processed per year by the laboratories. Most laboratories retained the specimens for at least 10 years. Institutional regulatory policies on sharing deidentified tissue varied considerably, ranging from requiring a full Institutional Review Board review to considering such use exempt from Institutional Review Board review, and 43% (55 of 127) of the laboratories did not know their terms for sharing tissue for research. CONCLUSIONS.: This project indicated a general willingness of pathology laboratories to participate in research by sharing FFPE tissue. Given the variability of research policies across laboratories, it is critical for each SEER registry to work with laboratories in their catchment area to understand such policies and state legislation regulating tissue retention and guardianship.